Klin Onkol 2005; 18(6): 210-215.
Abstract: Treatment with bisphosphonates is a standard supportive care in osteoporosis, Paget disease, metastatic bone disease and in multiple myeloma. One of the newest members of this group is ibandronate. The molecule of ibandronate contains nitrogen, therefore, some authors classify it as aminobisphosponate. Both peroral and intravenous forms are available. The same efficacy was confirmed in both drug forms. Adverse reactions of ibandronat are the ones charecteristic for aminonobisphosphonates. The peroral form reportedly has the lowest rate of adverse reactions from all commercialy available peroral bisphosphonates. No toxic effect on renal parenchyma and no renal function alteration were registered. Ibandronate is effective in treatment of hypercalceamia, malignant osteolysis, and osteoporosis; it also reduces pain in metastatic bone disease.
